Selected publications

OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Fanny Polesso, Minhaz Sarker, Andrew D. Weinberg, Susan E. Murray and Amy E. Moran
J Immunol August 21, 2019, ji1900696; DOI:

Late stage tumor regression after PD-L1 blockade with a concurrent OX40 agonist.
Polesso F, Weinberg A, Moran AE.
Cancer Immunol Res. 2018 Dec 18. pii: canimm.0222.2018. doi: 10.1158/2326-6066.CIR-18-0222. [Epub ahead of print.]
PMID: 30563828.

Immunotherapy expands and maintains the function of high affinity tumor infiltrating CD8 T cells in situ.
Moran AE, Polesso F, Weinberg AD.
(2016) Journal of Immunology. Aug 8 epub.
PMID: 27503208.

B-Raf is required for positive selection and survival of DP cells, but not for negative selection of SP cells.
Dillon TJ, Takahashi M, Li Y, Tavisala S, Murray SE, Moran AE, Parker DC, Stork PJ.
(2013). International Immunology. April 25(4):259-69.

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE, Kovacsovics-Bankowski M, Weinberg AD.
(2013). Current Opinion in Immunology. April 25(2):230-7.

Antigen-Independent Differentiation and Maintenance of Effector-like Resident Memory T cells in Tissues.
Casey KA, Fraser KA, Schenkel JM, Moran AE, Abt MC, Beura LK, Lucas PJ, Artis D, Wherry EJ, Hogquist K, Vezys V, Masopust D.
(2012). Journal of Immunology. May 15; 188(10): 4866-75.
PMID: 22504644.

T cell receptor affinity in thymic development.
Moran AE, Hogquist KA.
(2012). Immunology. April; 135(4):261-7.
PMID: 22182461.

T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse.
Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA.
(2011). Journal of Experimental Medicine. May 23, Epub.
PMCID: 3173240.

Treg cells meet their limit.
Hogquist KA & Moran AE.
Nature Immunology. 2009 June 6 (10):565-6.

A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions.
Wirth, LJ, Krane, JF, Li Y, Othus, M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM.
Cancer Prevention Research. 2008 Oct 1; (5):339-48.

Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxegenase-2 inhibitor. 
*Moran AE, *Carothers AM, Cho NL, Redston M, Bertagnolli MM.
Cancer Research. 2006 Sep 5; 114(10):1028-35 *equal contribution.

Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomysin contractility.
Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM.
Experimental Cell Research 2006 Feb 15; 312(4):387-400.

Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse.
Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM.
Cancer Research. 2005 Feb 1; 65(3):1097-104.

Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal tumorigenesis.
Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM.
Carcinogenesis. 2005 Mar; 26(3):587-95.

Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.
Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM.
Journal of Biological Chemistry. 2004 Oct 8; 279(41):43261-72.

Phytoestrogen-mediated suppression of Apc-associated intestinal tumorigenesis.
Javid SA; Moran AE; Carothers AM, and Bertagnolli MM.
Journal of Surgical Research, Oct. 2003.